

23rd October, 2026

The Manager,
Listing Compliance Department,
National Stock Exchange of India Ltd.,
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai 400051

Dear Sir,

Sub: Outcome of Board Meeting - submission of Unaudited Financial Results & Limited Review Reports (Standalone & Consolidated) for the quarter ended on 30th September, 2026

We refer to our letter dated 20th October, 2026 informing the date of Meeting of the Board of Directors of the Company.


Please note that the Board of Directors of the Company ('the Board'), in their meeting held today, *inter alia*, have taken on record the Unaudited Financial Results for the quarter ended on 30th September, 2026.

Pursuant to Regulation 33 of SEBI (LODR) Regulations, 2015, we are enclosing herewith the Statement of Unaudited Financial Results (Standalone and Consolidated) for the quarter ended on 30th September, 2026 – Integrated Filing (Financial) along with Auditors' Limited Review Report thereon as Annexure.

The Meeting of the Board of Directors was commenced at 11:30 am and concluded at 12:15 pm.

Thanking you.

Yours faithfully,
FOR SAKAR HEALTHCARE LIMITED


SANJAY S. SHAH
MANAGING DIRECTOR
(DIN: 01515296)



SHAH
SANJAYBHAI

Digitally signed by SHAH
SANJAYBHAI
Date: 2026.10.23 12:15:52
+05'30'

Encl: As above

**STATEMENT OF STANDALONE UNAUDITED RESULTS
FOR THE QUARTER AND SIX MONTHS ENDED ON 30TH SEPTEMBER, 2026**

(Rs. In lakh)

Particulars		Quarter ended on			Half Year ended on (Cumulative)		Previous Year ended on
		30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	31-03-2026
(Refer Notes Below)		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	8741.61	7297.25	5756.04	16038.86	11029.66	25173.60
2	Other income	28.13	154.39	121.46	182.52	160.85	228.74
3	Total Income (1+2)	8769.74	7451.64	5877.50	16221.38	11190.51	25402.34
4	Expenses						
	a. Cost of Materials consumed	4906.93	4003.52	2961.01	8910.45	5836.74	13268.83
	b. Purchases of stock-in-trade	-	-	-	-	-	-
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(333.37)	(545.30)	79.63	(878.67)	99.14	(941.16)
	d. Employee benefits expense	976.16	1145.51	834.19	2121.67	1589.15	3871.69
	e. Finance costs	200.40	166.97	152.68	367.37	366.94	785.59
	f. Depreciation & amortisation expense	660.22	654.24	568.38	1314.46	1125.61	2356.45
	g. Other expenses	757.36	568.63	745.82	1325.99	1098.66	2085.42
	Total Expenses	7167.70	5993.57	5341.71	13161.27	10116.24	21426.82
5	Profit before exceptional items and tax (3-4)	1602.04	1458.07	535.79	3060.11	1074.27	3975.52
6	Exceptional items						-
7	Profit before tax (5-6)	1602.04	1458.07	535.79	3060.11	1074.27	3975.52
8	Tax expense:						
	Current tax	398.70	393.42	100.90	792.12	191.19	675.68
	Deferred tax	72.65	36.16	81.81	108.81	153.16	304.11
	MAT Credit Entitlement	-	-	(100.90)	-	(191.19)	(52.73)
9	Profit for the period from continuing operations (7-8)	1130.69	1028.49	453.98	2159.18	921.11	3048.46
10	Profit from discontinuing operations before Tax		-	-	-	-	-
11	Tax expense of discontinuing operations		-	-	-	-	-
12	Profit from Discontinuing operations (after tax) (10-11)		-	-	-	-	-
13	Profit for the period (9+12)	1130.69	1028.49	453.98	2159.18	921.11	3048.46



Particulars		Quarter ended on			Half Year ended on (Cumulative)		Previous Year ended on 31-03- 2026
		30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
14	Other Comprehensive Income						
	<i>Items that will not be reclassified subsequently to profit or loss</i>						
	Re-measurement gains/(losses) on defined benefit plans	(3.70)	(3.70)	(3.70)	(7.40)	(7.40)	(14.80)
	Income tax relating to items that will not be reclassified to profit or loss	1.03	1.03	1.03	2.06	2.06	4.12
	<i>Items that will be reclassified subsequently to profit or loss</i>						
	Income tax relating to items that will be reclassified to profit or loss			-	-	-	
	Other Comprehensive Income, net of tax	(2.67)	(2.67)	(2.67)	(5.34)	(5.34)	(10.68)
15	Total Comprehensive Income for the period (13+14)	1128.02	1025.82	451.31	2153.84	915.77	3037.77
16	Paid-up equity shares capital (Face Value per share Rs. 10/-)	2224.99	2224.99	2224.99	2224.99	2224.99	2224.99
17	Reserves excluding Revaluation Reserves						30228.78
18	Earnings Per Share of Rs. 10/- each (for continuing operations)						
	- Basic	5.08	4.62	2.03	9.70	4.14	13.70
	- Diluted	5.08	4.62	2.03	9.70	4.14	13.70
19	Earnings Per Share of Rs. 10/- each (for discontinued operations)						
	- Basic		-	0.00		-	
	- Diluted		-	0.00		-	
20	Earnings Per Share of Rs. 10/- each (for discontinued & continuing operations)						
	- Basic	5.08	4.62	2.03	9.70	4.14	13.70
	- Diluted	5.08	4.62	2.03	9.70	4.14	13.70



STATEMENT OF STANDALONE ASSETS AND LIABILITIES

(Rs. In lakh)

Sr.No.	Particulars	As at 30-09-2026 (Unaudited)	As at 31-03-2026 (Audited)
	ASSETS		
1	Non-Current Assets		
	Property, plant and equipment	32089.98	31905.90
	Capital work-in-progress	576.76	396.53
	Investment property		
	Goodwill		
	Other intangible Assets	1268.32	742.70
	Intangible Assets under development		
	Biological Assets other than bearer plants		
	Non-Current Financial Assets:		
	(i) Investments, Non-Current	1.00	1.00
	(ii) Trade receivables, Non-Current		
	(iii) Loans, Non-Current	30.06	30.06
	Deferred tax Assets (net)		
	Other Non-Current Assets	1548.78	979.90
	Total Non-Current Assets	35514.90	34056.09
2	Current Assets		
	Inventories	9720.52	7004.14
	Current financial asset:		
	(i) Current investments		
	(ii) Trade receivables, Current	3940.87	5008.33
	(iii) Cash and cash equivalents	4.58	4.02
	(iv) Bank balance other than above	21.75	21.75
	(v) Loans, Current	7.72	7.72
	(vi) Other Current financial Assets		
	Current tax Assets (net)		
	Other Current Assets	2371.12	2007.40
	Total Current Assets	16066.56	14053.36
	TOTAL ASSETS	51581.46	48109.45



	EQUITY AND LIABILITIES		
1	Equity		
	Equity share capital	2224.99	2224.99
	Other Equity	32382.65	30228.78
	Money Received Against Share Warrant	-	-
	Total Equity	34607.64	32453.77
2	Liabilities		
	Non-Current Liabilities		
	Non-Current financial Liabilities:		
	(i) Borrowings, Non-Current	3301.14	3135.30
	(ii) Trade payables, Non-Current		
	(a) total outstanding dues of micro enterprises and small enterprises		
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises		
	(iii) Other Non-Current financial Liabilities		
	Provisions, Non-Current	288.25	280.84
	Deferred tax Liabilities (net)	1392.57	1285.82
	Other Non-Current Liabilities		
	Total Non-Current Liabilities		
	Current Liabilities	4981.96	4701.96
	Current financial Liabilities:		
	(i) Borrowings, Current	1300.98	2395.09
	(ii) Trade payables, Current		
	(a) total outstanding dues of micro enterprises and small enterprises		
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	6225.06	5154.00
	(iii) Other Current financial Liabilities	1613.00	1523.00
	Other Current Liabilities	1969.77	1017.43
	Provisions, Current		
	Current tax Liabilities (Net)	883.05	864.19
	Total Current Liabilities	11991.86	10953.71
	Total Liabilities	16973.82	15655.67
	TOTAL EQUITY AND LIABILITIES	51581.46	48109.45





Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 **Fax:** 02717-251621 **Email:** info@sakarhealthcare.com **Web:** www.sakarhealthcare.com

STATEMENT OF STANDALONE CASH FLOWS FOR THE PERIOD

FROM 1ST APRIL, 2026 TO 30TH SEPTEMBER, 2026 (HALF-YEAR)

(Rs. In Lakh)

Particulars	For the Half year ended on 30th September, 2026	For the Half year ended on 30th September, 2025
Profit before Taxes	3060.11	1074.27
Adjustments:		
Depreciation	1314.46	1125.61
Interest Expense	303.03	355.38
Provision for Doubtful Debts	2.76	2.24
Unrealized Loss/ (Gain) On Mutual Fund		
Amortized Loan Processing Fees	3.49	2.88
Actuarial gain/(Loss) Employee Benefit Expenses	(7.40)	(7.40)
Changes in Working Capital		
Inventories	(2716.38)	(93.41)
Financial assets		
- Trade receivables	1064.70	(128.47)
- Loans and Advances		
- Short Term Investments		
Other current assets	(363.72)	(379.89)
Other Non- Current Assets		
MAT Credit		
Financial assets		
- Loans and Advances		
Other non-current assets	(568.88)	(1129.14)
Financial liabilities		
- Borrowings	(1094.11)	524.50
- Trade Payables	1071.10	1496.11
- Other financial liabilities	1042.34	316.62
Other current liabilities		
Provisions	(613.91)	177.94
Cashflow from Operating Activity before Taxes	2497.59	3337.24
Net Tax Paid	(151.95)	(278.53)
Net Cashflow from Operating Activity	2345.64	3058.71
Cashflow from Investing Activity		
Purchase of Property, Plant & Equipments	(2204.39)	(2739.95)
Proceed From Sale of Investment		
Purchase of Mutual Fund		
Purchase of Intangible Assets		
Net Cashflow from Investing Activity	(2204.39)	(2739.95)
Cashflow from Financing Activity		
Proceeds from issue of shares	-	864.00
Proceeds / (Repayment) of Borrowings	165.84	(833.82)
Interest Paid	(303.03)	(355.38)
Payment Of Loan Processing Fees	(3.49)	(2.88)
Net Cashflow from Financing Activity	(140.68)	(328.08)
Net Cash Inflow / (Outflow)	0.57	(9.32)
Opening Cash and Cash Equivalent	4.01	9.96
Closing Cash and Cash Equivalent	4.58	0.64

for SAKAR HEALTHCARE LIMITED



Sanjay S. Shah
SANJAY S. SHAH
MANAGING DIRECTOR
(DIN : 01515296)

Date: 23rd October 2026

Place: Ahmedabad

Corporate Office: 406, silver Oaks Commercial Complex, Opp. Arun Society, Paldi, Ahmedabad – 380 007

Phone: 079-26584655 **Fax:** 079-26588054

Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: info@sakarhealthcare.com Web: www.sakarhealthcare.com

Notes:

1	The Company is operating only in one segment i.e. Manufacturing Of Pharmaceutical Products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. Hence segment reporting is not given.
2	The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
3	The Company has a wholly owned subsidiary viz. Sakar Oncology Private Limited. Other than this, the Company does not have any subsidiary/associate.
4	Provision for taxation/deferred taxation, if any, will be made at the year end.
5	Figures, wherever required, are regrouped/ rearranged. There are no material adjustments made in the results of the earlier periods.
6	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 23 rd October 2026.

Date: 23rd October 2026
Place: Ahmedabad

for SAKAR HEALTHCARE LIMITED




SANJAY S. SHAH
MANAGING DIRECTOR
(DIN : 01515296)



J. S. SHAH & CO.

Chartered Accountants

**LIMITED REVIEW REPORT ON UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE PERIOD ENDED
30TH SEPTEMBER 2026**

Review report to the Board of Directors of Sakar Healthcare Limited


We have reviewed the accompanying statement of unaudited standalone financial results of Sakar Healthcare Limited for the period ended **30th September 2026** ("the statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, as amended ("the Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement(s). A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For J S Shah & Co
Chartered Accountants
FRN: 132059W


Jaimin S Shah
Partner

Place: Ahmedabad
Date: 23rd October 2026

(Membership No. 138488)
(UDIN: 26138488QZPTUI3859)

**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS
FOR THE QUARTER ENDED ON 30TH SEPTEMBER, 2026**

(Rs. In lakh)

(Refer Notes Below)		Quarter ended on			Half Year ended on (Cumulative)		Previous Year ended on 31-03-2026
		30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Revenue from operations	8741.61	7297.25	5756.04	16038.86	11029.66	25173.60
2	Other income	28.13	154.39	121.46	182.52	160.85	228.74
3	Total Income (1+2)	8769.74	7451.64	5877.50	16221.38	11190.51	25402.34
4	Expenses						
	a. Cost of Materials consumed	4906.93	4003.52	2961.01	8910.45	5836.74	13268.83
	b. Purchases of stock-in-trade	-	-	-	-		
	c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(333.37)	(545.30)	79.63	(878.67)	99.14	(941.16)
	d. Employee benefits expense	976.16	1145.51	834.19	2121.67	1589.15	3871.69
	e. Finance costs	200.40	166.97	152.68	367.37	366.94	785.59
	f. Depreciation & amortisation expense	660.22	654.24	568.38	1314.46	1125.61	2356.45
	g. Other expenses	757.36	568.63	745.82	1325.99	1098.66	2085.42
	Total Expenses	7167.70	5993.57	5341.71	13161.27	10116.24	21426.82
5	Profit before exceptional items and tax (3-4)	1602.04	1458.07	535.79	3060.11	1074.27	3975.52
6	Exceptional items		-				-
7	Profit before tax (5-6)	1602.04	1458.07	535.79	3060.11	1074.27	3975.52
8	Tax expense:						
	Current tax	398.70	393.42	100.90	792.12	191.19	675.68
	Deferred tax	72.65	36.16	81.81	108.81	153.16	304.11
	MAT Credit Entitlement	-	-	(100.90)	-	(191.19)	(52.73)
9	Profit for the period from continuing operations (7-8)	1130.69	1028.49	453.98	2159.18	921.11	3048.46
10	Profit from discontinuing operations before Tax		-	-	-	-	-
11	Tax expense of discontinuing operations		-	-	-	-	-
12	Profit from Discontinuing operations (after tax) (10-11)		-	-	-	-	-
13	Share of profit of associates and joint ventures accounted for using equity method	1130.69	1028.49		2159.18	-	-
14	Profit for the period (9+12+13)	1130.69	1028.49	453.98	2159.18	921.11	3048.46
	Attributable to owner of parent	1130.69	-	453.98	2159.18	921.11	3048.46
	Attributable to Non-controlling interests	-	-		-	-	-



Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 **Fax:** 02717-251621 **Email:** info@sakarhealthcare.com **Web:** www.sakarhealthcare.com

(Refer Notes Below)		Quarter ended on			Half Year ended on (Cumulative)		Previous Year ended on
		30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	31-03-2026
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
15	Other Comprehensive Income						
	<i>Items that will not be reclassified subsequently to profit or loss</i>						
	Re-measurement gains/(losses) on defined benefit plans	(3.70)	(3.70)	(3.70)	(7.40)	(7.40)	(14.80)
	Income tax relating to items that will not be reclassified to profit or loss	1.03	1.03	1.03	2.06	2.06	4.12
	<i>Items that will be reclassified subsequently to profit or loss</i>						
	Income tax relating to items that will be reclassified to profit or loss		-	-	-	-	
	Other Comprehensive Income, net of tax	(2.67)	(2.67)	(2.67)	(5.34)	(5.34)	(10.68)
	Attributable to owner of parent	(2.67)	(2.67)	(2.67)	(5.34)	(5.34)	(10.68)
	Attributable to Non-controlling interests						
16	Total Comprehensive Income for the period (14+15)	1128.02	1025.82	451.31	2153.84	915.77	3037.77
	Attributable to owner of parent	1128.02	1025.82	451.31	2153.84	915.77	3037.77
	Attributable to Non-controlling interests		-				
17	Paid-up equity shares capital (Face Value per share Rs. 10/-)	2224.99	2224.99	2224.99	2224.99	2224.99	2224.99
18	Reserves excluding Revaluation Reserves						30220.26
19	Earnings Per Share of Rs. 10/- each (for continuing operations)						
	- Basic	5.08	4.62	2.03	9.70	4.14	13.70
	- Diluted	5.08	4.62	2.03	9.70	4.14	13.70
20	Earnings Per Share of Rs. 10/- each (for discontinued operations)						
	- Basic	-	-	0.00	-	-	
	- Diluted	-	-	0.00	-	-	
21	Earnings Per Share of Rs. 10/- each (for discontinued & continuing operations)						
	- Basic	5.08	4.62	2.03	9.70	4.14	13.70
	- Diluted	5.08	4.62	2.03	9.70	4.14	13.70



Corporate Office: 406, silver Oaks Commercial Complex, Opp. Arun Society, Paldi, Ahmedabad – 380 007

Phone: 079-26584655 **Fax:** 079-26588054

STATEMENT OF CONSOLIDATED ASSETS AND LIABILITIES

(Rs. In lakh)

Sr.No.	Particulars	As at 30-09-2026 (Unaudited)	As at 31-03-2026 (Audited)
	ASSETS		
1	Non-Current Assets		
	Property, plant and equipment	32089.98	31905.90
	Capital work-in-progress	576.76	396.53
	Investment property		
	Goodwill		
	Other intangible Assets	1268.32	742.70
	Intangible Assets under development		
	Biological Assets other than bearer plants		
	Non-Current Financial Assets:		
	(i) Investments, Non-Current		
	(ii) Trade receivables, Non-Current		
	(iii) Loans, Non-Current	30.06	30.06
	Deferred tax Assets (net)		
	Other Non-Current Assets	1548.78	979.90
	Total Non-Current Assets	35513.90	34,055.09
2	Current Assets		
	Inventories	9720.52	7,004.14
	Current financial asset:		
	(i) Current investments		
	(ii) Trade receivables, Current	3940.87	5,008.33
	(iii) Cash and cash equivalents	4.78	4.22
	(iv) Bank balance other than above	21.75	21.75
	(v) Loans, Current	-	-
	(vi) Other Current financial Assets		
	Current tax Assets (net)	-	-
	Other Current Assets	2371.11	2,007.42
	Total Current Assets	16059.03	14,045.86
	TOTAL ASSETS	51572.93	48,100.95



(Rs. In lakh)			
Sr.No.	Particulars	As at 30-09-2026 (Unaudited)	As at 31-03-2026 (Audited)
	EQUITY AND LIABILITIES		
1	Equity		
	Equity share capital	2224.99	2,224.99
	Other Equity	32374.12	30,220.26
	Money Received Against Share Warrant		-
	Total Equity	34599.11	32,445.25
2	Liabilities		
	Non-Current Liabilities		
	Non-Current financial Liabilities:		
	(i) Borrowings, Non-Current	3301.14	3,135.30
	(ii) Trade payables, Non-Current		
	(a) total outstanding dues of micro enterprises and small enterprises		
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises		
	(iii) Other Non-Current financial Liabilities		
	Provisions, Non-Current	288.25	280.84
	Deferred tax Liabilities (net)	1392.57	1,285.82
	Other Non-Current Liabilities		
	Total Non-Current Liabilities	4981.96	4,701.96
	Current Liabilities		
	Current financial Liabilities:		
	(i) Borrowings, Current	1300.98	2,395.09
	(ii) Trade payables, Current		
	(a) total outstanding dues of micro enterprises and small enterprises		
	(b) total outstanding dues of creditors other than micro enterprises and small enterprises	6225.06	5,154.00
	(iii) Other Current financial Liabilities	1613.00	1,523.00
	Other Current Liabilities	1969.77	1,017.43
	Provisions, Current		
	Current tax Liabilities (Net)	883.05	864.19
	Total Current Liabilities	11991.86	10,953.71
	Total Liabilities	16973.82	15,655.67
	TOTAL EQUITY AND LIABILITIES	51572.93	48,100.92





[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 **Fax:** 02717-251621 **Email:** info@sakarhealthcare.com **Web:** www.sakarhealthcare.com

Notes:

1	The Company is operating only in one segment i.e. Manufacturing Of Pharmaceutical Products providing Liquid Orals, Cephalosporin Tablet, Capsule, Dry Powder Syrup, Dry Powder Injections, Liquid Injectables (SVP) in Ampoules and Vials & Lyophilized Injections. Hence segment reporting is not given.
2	The consolidated results of the Company are comprising of wholly owned subsidiary of the Company viz. Sakar Oncology Private Limited. Other than this, the Company does not have any subsidiary/associate.
3	The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
4	Provision for taxation/deferred taxation, if any, will be made at the year end.
5	Figures, wherever required, are regrouped/ rearranged. There are no material adjustments made in the results of the earlier periods.
6	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 23 rd October 2026.
7	Further, the figures of Standalone and Consolidated Financial Results are identical since the subsidiary company has not carried out any business transactions during the relevant reporting period. Accordingly, there is no impact on the consolidated financial statements, resulting in the same figures as the standalone financials.

Date: 23rd October 2026
Place: Ahmedabad



for SAKAR HEALTHCARE LIMITED


SANJAY S. SHAH
MANAGING DIRECTOR
(DIN : 01515296)

**STATEMENT OF CONSOLIDATED CASH FLOWS FOR THE PERIOD
FROM 1ST APRIL, 2026 TO 30TH SEPTEMBER, 2026 (HALF-YEAR)**

Particulars	For the Half year ended on 30th September, 2026	For the Half year ended on 30th September, 2025
Profit before Taxes	3060.11	1074.27
Adjustments:		
Depreciation	1314.46	1125.61
Interest Expense	303.03	355.38
Provision for Doubtful Debts	2.76	2.24
Unrealised Loss/(Gain)On Mutual Fund		
Amortised Loan Processing Fees	3.49	2.88
Changes in Other Equity	(7.40)	(7.40)
Changes in Working Capital		
Inventories	(2716.38)	(93.41)
Financial assets		
- Trade receivables	1064.70	(128.47)
- Loans and Advances		
- Short Term Investments		
Other current assets	(363.72)	(379.89)
MAT Credit		
Financial assets		
- Loans and Advances		
Other non-current assets	(568.88)	(1129.14)
Financial liabilities		
- Borrowings	(1094.11)	524.50
- Trade Payables	1071.10	1496.11
- Other financial liabilities	1042.34	316.62
Other current liabilities		
Provisions	(613.91)	177.94
Cashflow from Operating Activity before Taxes	2497.59	3337.24
Net Tax Paid	(151.95)	(278.53)
Net Cashflow from Operating Activity	2345.64	3058.71
Cashflow from Investing Activity		
Purchase of Property, Plant & Equipments	(2204.39)	(2739.95)
Purchase of Mutual Fund		
Purchase of Intangible Assets		
Proceed from Sale of Investment		
Net Cashflow from Investing Activity	(2204.39)	(2739.95)
Cashflow from Financing Activity		
Proceeds from issue of shares	-	864.00
Proceeds / (Repayment) of Borrowings	155.84	(833.82)
Payment Of Loan Processing Fees	(3.49)	(2.88)
Interest Paid	(303.03)	(355.38)
Net Cashflow from Financing Activity	(140.68)	(328.08)
Net Cash Inflow / (Outflow)	0.57	(9.32)
Opening Cash and Cash Equivalent	4.21	10.16
Closing Cash and Cash Equivalent	4.78	0.84

Date: 23rd October 2026

Place: Ahmedabad



for SAKAR HEALTHCARE LIMITED
Sanjay S. Shah
SANJAY S. SHAH
MANAGING DIRECTOR
(DIN : 01515296)



**LIMITED REVIEW REPORT ON UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE PERIOD ENDED
30TH SEPTEMBER 2026**

Review report to the Board of Directors of Sakar Healthcare Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of Sakar Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/ (loss) after tax and total comprehensive income / loss of its associates and joint ventures for the quarter ended **30th September 2026** and for the period from **1st April 2026 to 30th September 2026** ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 30th September 2025 and the corresponding period from 1st April 2025 to 30th September 2026, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

Sakar Oncology Private Limited

5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.
6. We did not review the interim financial information of Sakar Oncology Private Limited subsidiaries included in the consolidated unaudited financial results, whose interim financial information reflects, total revenues of NIL, total net profit after tax of NIL, total comprehensive income of NIL for the quarter ended September 30, 2026, as considered in the Statement. These interim financial information have been reviewed by other auditors whose reports have been furnished to us by the Management and our conclusion on the Statement, in so far as it relates to the amounts and disclosures included in respect of these subsidiaries, is based solely on the reports of the other auditors and the procedures performed by us as stated in paragraph 3 above.

Our conclusion on the Statement is not modified in respect of the above matters

For J S Shah & Co
Chartered Accountants
FRN: 132059W



Jaimin S Shah
Partner

Place: Ahmedabad
Date: 23rd October 2026

(Membership No. 138488)
(UDIN: 26138488QEVIQB7468)

B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.

Not Applicable

C. FORMAT FOR DISCLOSING OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES:

Not Applicable

D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter) :

will be filed along with XBRL for financial results

E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4th quarter):

Not Applicable

Date : 23rd October, 2026
Place: Ahmedabad

FOR SAKAR HEALTHCARE LIMITED




SANJAY S. SHAH
MANAGING DIRECTOR
DIN: 01515296